FDA Testing and Safety of Wegovy and Zepbound

Last updated 5 days ago. Our resources are updated regularly but please keep in mind that links, programs, policies, and contact information do change.

Wegovy and Zepbound have changed how doctors treat obesity. These drugs produce weight loss that rivals surgery: semaglutide delivers an average 14.9% body weight reduction, while tirzepatide achieves up to 20.9%. But their popularity has raised urgent questions about safety and the rigor of government testing.

This report examines the complete regulatory process these drugs went through, from animal studies to ongoing post-market surveillance. It covers the clinical trials, manufacturing inspections, enforcement actions against misleading advertising, and the risks of unregulated compounded versions.

How FDA Approval Works

The FDA’s Center for Drug Evaluation and Research controls which drugs reach the market under the Federal Food, Drug, and Cosmetic Act. Before any company can sell a new drug, it must prove both safety and efficacy.

Before Human Testing Begins

Novo Nordisk (semaglutide) and Eli Lilly (tirzepatide) had to submit Investigational New Drug applications before testing in humans. The FDA’s review at this stage focuses heavily on animal toxicology studies.

For these GLP-1 drugs, animal testing found thyroid C-cell tumors in rodents. This finding led to the “Black Box” warnings you now see on the labels. FDA reviewers examine organ toxicity in multiple species, typically rats, mice, and monkeys, to predict problems in humans.

The Three Phases of Clinical Trials

Phase 1 enrolled small groups of 20 to 80 people. The goal wasn’t weight loss but understanding how the body processes the drug. For tirzepatide, Phase 1 established that once-weekly dosing was feasible and identified early gastrointestinal side effects.

Phase 2 expanded to several hundred patients. These trials determine optimal dosing—how fast to increase the dose to minimize side effects. The signature nausea and vomiting profile emerged here, leading to the gradual dose-escalation schedules doctors now use.

Phase 3 is where efficacy gets proven. Thousands of patients across multiple countries participated. For Wegovy, this was the STEP program. For Zepbound, SURMOUNT. These randomized, double-blind trials provided the evidence for FDA approval.

The FDA participates in designing these trials, typically through “End-of-Phase 2” meetings where endpoints and safety protocols are agreed upon.

Fast-Track Designations

Zepbound received Fast Track designation for treating obstructive sleep apnea and obesity, plus Priority Review for its obesity indication. These designations are reserved for drugs addressing serious unmet medical needs. They allow more frequent FDA interaction and cut review time from 10 months to 6.

Wegovy received Breakthrough Therapy designation for treating metabolic-associated steatohepatitis (MASH), a serious liver disease.

The Inspection Program No One Talks About

The FDA doesn’t just accept data from pharmaceutical companies. Through its Bioresearch Monitoring program, FDA inspectors visit clinical trial sites, the actual doctors’ offices, and hospitals where studies are run.

Inspectors verify source data by checking patient medical records against what was submitted to the FDA. They confirm informed consent was obtained and the protocol was followed. If they find problems, data can be excluded from the approval decision.

How These Drugs Work

Semaglutide mimics GLP-1, a hormone secreted by intestinal cells after eating. Natural GLP-1 breaks down in minutes, but semaglutide is engineered to last a week. It acts on the brain to increase satiety and reduce hunger. It also delays how fast food leaves the stomach, which explains the gastrointestinal side effects.

Tirzepatide adds a second mechanism; it also activates the GIP receptor. This “dual agonist” approach enhances insulin secretion and changes fat metabolism. Early data suggested GIP might reduce nausea while boosting weight loss, a hypothesis tested in the SURMOUNT trials.

The STEP Trials for Wegovy

The STEP program was one of the largest obesity trial programs ever conducted.

STEP 1: The Main Trial

STEP 1 enrolled 1,961 adults with BMI ≥30 (or ≥27 with weight-related health problems), excluding people with diabetes. The trial ran at 129 sites globally for 68 weeks.

Participants received either semaglutide 2.4 mg or placebo, with lifestyle counseling for both groups. The semaglutide group lost an average of 14.9% of body weight compared to 2.4% for placebo. More significantly, 86.4% of semaglutide users lost at least 5% of their weight—the FDA’s threshold for clinical meaningfulness.

STEP 2: Testing in Diabetics

People with type 2 diabetes are notoriously resistant to weight loss. STEP 2 showed 9.6% weight loss for semaglutide versus 3.4% for placebo. The FDA considered this highly significant given the metabolic challenges of diabetic patients.

STEP Teens: Pediatric Testing

The FDA required testing in adolescents, a vulnerable population. STEP Teens enrolled 201 adolescents aged 12-17. Results mirrored adult data: BMI dropped 16.1% for semaglutide versus a 0.6% increase for placebo.

This data supported expanding the indication to adolescents 12 and older, though with heightened monitoring for growth and development.

SELECT: The Game Changer

The SELECT trial followed 17,604 adults aged 45+ with overweight/obesity and established cardiovascular disease but without diabetes. The trial measured cardiovascular death, heart attack, and stroke.

Semaglutide reduced the risk of these major cardiac events by 20% compared to placebo. In March 2024, the FDA approved a new indication for Wegovy to reduce cardiovascular risk. This transformed the drug from a “lifestyle” medication to essential cardiovascular therapy.

The SURMOUNT Trials for Zepbound

The SURMOUNT program aimed to prove that the dual-agonist mechanism was superior.

SURMOUNT-1: Setting New Records

SURMOUNT-1 tested three doses of tirzepatide (5 mg, 10 mg, 15 mg) in 2,539 participants with obesity or overweight plus at least one weight-related complication, excluding diabetes.

At 72 weeks, weight dropped by 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg), compared to 3.1% for placebo. The 15 mg group lost an average of 52 pounds. The FDA review noted these results exceeded previous drug approvals.

SURMOUNT-2: Diabetic Validation

Like STEP 2, this trial confirmed the drug works in people with type 2 diabetes. The 15 mg dose achieved 15.7% weight reduction.

Clinical Trial Results Summary

Safety Risks Identified by the FDA

In regulatory terms, “safety” means a manageable risk profile where benefits outweigh harms. The FDA has identified specific organ-system risks now listed in product labels.

Gastrointestinal Problems

The most common side effects are gastrointestinal, a direct result of delayed stomach emptying.

Nausea occurred in roughly 44% of Wegovy patients and up to 30% of Zepbound patients in trials. Vomiting and diarrhea were also common.

More serious is gastroparesis (stomach paralysis) and ileus (intestinal blockage). Post-marketing reports led the FDA to update labels for both drugs to warn about ileus. While rare in clinical trials, the volume of real-world reports suggests some patients experience severe motility reduction.

Because the stomach may contain food even after fasting, there’s a risk of pulmonary aspiration during anesthesia. The American Society of Anesthesiologists issued guidance advising patients to withhold GLP-1 drugs before elective surgery to prevent aspiration pneumonia.

Thyroid Cancer Risk

The most prominent warning on the label is the Boxed Warning about thyroid C-cell tumors.

In rodent studies, both drugs caused dose-dependent thyroid C-cell tumors (adenomas and carcinomas) at clinically relevant exposures. The FDA says the human relevance is unclear because human C-cells have far fewer GLP-1 receptors than rodent C-cells.

Still, the “precautionary principle” dictated a strict contraindication. These drugs cannot be used in patients with a personal or family history of Medullary Thyroid Carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Pancreas and Gallbladder Issues

Both drugs carry warnings for acute pancreatitis. In SURMOUNT-1, rare cases occurred. Patients must discontinue immediately if they experience severe, persistent abdominal pain radiating to the back.

Rapid weight loss is a known risk factor for gallstones. The trials confirmed a higher incidence of gallbladder-related events in treatment groups compared to placebo. This is likely a mechanical consequence of weight loss rather than direct drug toxicity.

Mental Health Concerns

Reports of suicidal ideation and “anhedonia” (loss of pleasure) attracted significant media attention.

In January 2024, the FDA completed a preliminary evaluation of adverse event reports and conducted meta-analyses of clinical trials. The agency concluded the data did not show a clear relationship between GLP-1 drugs and suicidal thoughts. However, it couldn’t definitively rule out a small risk and continues monitoring.

The debate often centers on whether reducing “food noise” (a therapeutic goal) differs from general anhedonia (a potential side effect). Current labeling advises monitoring for depression and suicidal thoughts as a precaution.

Kidney Injury Risk

There’s a risk of acute kidney injury, typically secondary to dehydration from severe nausea, vomiting, or diarrhea. The FDA mandates warnings advising patients to maintain hydration and physicians to monitor kidney function in patients with severe gastrointestinal side effects. This is preventable if managed correctly.

Complete Safety Warning Profile

Manufacturing Quality Problems

Drug safety depends on manufacturing quality. The FDA enforces Current Good Manufacturing Practice regulations through facility inspections.

Novo Nordisk Inspections

Novo Nordisk has faced scrutiny of its manufacturing facilities.

In March 2024, an FDA inspection of the Kalundborg, Denmark facility resulted in a Form 483 with eight observations. Inspectors cited deficiencies in water quality monitoring (essential for sterile injectables) and lack of written procedures to ensure drug quality and purity.

A previous inspection of a Catalent facility in Bloomington, Indiana (a contract manufacturer for Novo Nordisk) found significant violations including cat and human hair in vial stoppers and pest infestations. These findings show the fragility of the sterile manufacturing supply chain.

Eli Lilly Inspections

Eli Lilly has also received regulatory action. Inspections of Lilly facilities generated Form 483s citing inadequate executive oversight and control over drug manufacture. Issues with contract manufacturing organizations have previously delayed approvals.

The Oprah Video Warning Letters

The FDA’s Office of Prescription Drug Promotion monitors how companies communicate risk to the public. Misleading advertising is a safety risk because it distorts benefit-risk perception.

In September 2025, the FDA took enforcement action against both Novo Nordisk and Eli Lilly regarding “An Oprah Special: Shame, Blame, and the Weight Loss Revolution.”

The Warning Letters stated the video was “false or misleading.” It failed to adequately communicate the contraindication regarding thyroid cancer risk. It also omitted information about acute kidney injury, hypoglycemia, and diabetic retinopathy.

The video featured physicians who were paid consultants for the companies. The FDA said the promotional nature required full risk disclosure, which was absent.

The FDA explicitly stated these violations were concerning because they created a misleading impression of safety for drugs with “multiple serious, potentially life-threatening risks.”

Compounded Versions: A Separate Safety Problem

FDA-approved Wegovy and Zepbound differ significantly from compounded versions. Under Section 503A and 503B of the FD&C Act, compounding pharmacies can produce versions of drugs in “shortage.” But these products aren’t FDA-approved and don’t undergo the same testing.

The Salt Form Issue

The FDA has issued alerts about compounders using semaglutide sodium and semaglutide acetate. These salt forms differ chemically from the base form (semaglutide) in FDA-approved products.

The FDA says it’s not aware of any lawful basis for compounding these salt forms and they haven’t been evaluated for safety or efficacy. The agency has received adverse event reports specifically linked to these unapproved formulations.

Dosing Errors and Hospitalizations

The FDA has documented a surge in adverse events related to dosing errors with compounded products.

Unlike the pre-filled, single-dose pens of Wegovy and Zepbound, compounded products are often dispensed in multi-dose vials requiring patients to draw up medication with a syringe. This creates high risk of user error.

The FDA reported cases where patients accidentally administered 5 to 10 times the intended dose, resulting in severe nausea, intractable vomiting, dehydration, and hospitalization for acute kidney injury. These safety issues stem from the delivery format, not necessarily the molecule itself.

Ongoing Surveillance

Drug testing never stops. The FDA maintains surveillance systems to detect risks that may only appear after millions of users are exposed long-term.

The Adverse Event Reporting System

The FDA Adverse Event Reporting System (FAERS) serves as a repository for post-market safety reports.

Media reports have cited FAERS data linking 162 deaths to Ozempic/Wegovy (94 deaths) and Mounjaro/Zepbound (68 deaths). But a report in FAERS doesn’t prove causality—it only indicates an adverse event occurred while the patient was taking the drug.

Given the high comorbidities of obese and diabetic populations (who are at risk for sudden cardiac death), distinguishing drug effects from background disease requires sophisticated statistical analysis.

Signal Detection

The FDA uses this data to identify “signals.” Current signals under evaluation in 2024-2025 include alopecia (hair loss), aspiration, and suicidal ideation. When a signal is confirmed, the FDA mandates label updates or Risk Evaluation and Mitigation Strategies.

The Bottom Line on Safety

The FDA’s approval of Wegovy and Zepbound was based on unprecedented weight loss efficacy (15-20%), proven cardiovascular benefit (20% reduction in heart attacks and strokes for Wegovy), and identified safety risks with appropriate labeling and contraindications.

However, “safe” is conditional. It requires strict adherence to patient selection criteria (avoiding those with thyroid cancer history or severe gastroparesis), proper dose titration to avoid kidney injury, and avoiding unapproved compounded formulations that carry distinct, unverified risks.

The government’s ongoing enforcement, from warning letters about misleading advertisements to facility inspections identifying contamination, shows oversight is active and continuous. While the drugs are deemed safe for indicated populations, their rapid expansion requires continued vigilance for rare, long-term, and compounding-related adverse events.

Our articles make government information more accessible. Please consult a qualified professional for financial, legal, or health advice specific to your circumstances.